June 29, 2026 - Non-regulatory BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study
June 15, 2026 - Non-regulatory SynAct Pharma Board of Directors and Management Enter Lock-up Agreements
June 15, 2026 - Regulatory Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis – supports phase 3 design, regulatory interactions, and partnering
June 12, 2026 - Non-regulatory SynAct obtains key US patent for resomelagon securing exclusivity until 2044
May 6, 2026 - Non-regulatory SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study
May 5, 2026 - Non-regulatory SynAct Pharma to participate at the LSX Nordic Congress on May 19-20, 2026 in Copenhagen
April 23, 2026 - Regulatory SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting
March 26, 2026 - Non-regulatory SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon
March 18, 2026 - Non-regulatory SynAct Pharma Presenting at Partnering and Investor Conference BIO-Europe Spring® 2026 on March 23-25
March 4, 2026 - Non-regulatory Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11
March 2, 2026 - Regulatory SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK
March 2, 2026 - Regulatory SynAct Pharma announces intention to carry out a directed issue of approximately 45 MSEK
February 6, 2026 - Non-regulatory SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study
January 9, 2026 - Regulatory The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares
